Olema Oncology Awarded State Grant for Workforce Training
Olema Oncology has been awarded $60,000 in state funding to support the training of 37 employees.
Stocks · News reference
Citigroup Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $59
Citigroup analyst Yigal Nochomovitz maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and lowers the price target from $62 to $59.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Olema Pharmaceuticals, Inc. (OLMA)
Filed: 2026-10-15 AccNo: 0001193125-26-423002 Size: 148 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Stifel Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $30
Stifel analyst Laura Prendergast maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and lowers the price target from $48 to $30.
Corning, Cellectis, Biodexa Pharmaceuticals And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
U.S. stock futures fell, with Nasdaq 100 futures down 500 points. Corning dropped 8% after a $2B offering; several other stocks also slid premarket.